COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s): CSCI

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:CSCI - Post by User

COSCIENS Biopharma Inc > New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Aug 13, 2024 10:56am

52 Views

Post# 36176519

RE:RE:New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Ceapro revenues up from q1 24 after factoring in fx...

	Cdn	Cdn
	Revenues	Gross profit	Gross margin
Q2 24	3,194,312	1,120,883	35.1%
Q1 24	2,773,788	1,218,406	43.9%
Q4 23	1,650,858	200,058	12.1%
Q3 23	2,618,973	1,080,023	41.2%
Q2 23	1,868,758	1,070,270	57.3%
Q1 23	3,494,811	1,605,838	45.9%
Q4 22	3,322,214	1,204,000	36.2%
Q3 22	3,845,370	2,077,970	54.0%
Q2 22	5,500,399	3,639,335	66.2%
Q1 22	6,171,624	3,954,609	64.1%